CD8A and cancer: Interestingly, increased expression of the inhibitory heterodimer receptors NKG2A+ and CD94+ on CD8+ T cells, both in murine cancer models and in patients with advanced melanoma, resulted from blocking both LAG-3 and PD1 [60], possibly as a compensatory mechanism to prevent immunopathology.